Pharming Group (PHAR)
(Delayed Data from NSDQ)
$7.59 USD
-0.46 (-5.66%)
Updated Sep 20, 2024 03:03 PM ET
After-Market: $7.76 +0.18 (2.31%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.59 USD
-0.46 (-5.66%)
Updated Sep 20, 2024 03:03 PM ET
After-Market: $7.76 +0.18 (2.31%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
by Zacks Equity Research
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
Why Earnings Season Could Be Great for Pharming Group (PHAR)
by Zacks Equity Research
Pharming Group (PHAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
by Zacks Equity Research
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Pharming Group N.V. Sponsored ADR (PHAR) and POINT Biopharma Global Inc. (PNT) have performed compared to their sector so far this year.
Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Pharming Group N.V. Sponsored ADR (PHAR) have performed compared to their sector so far this year.